Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 9/20 | 0.44 |
| ▸ | CTSS | P25774 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 3/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15110725 | 0.84 | CA1 (0.49) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL22404434 | 0.83 | CA1 (0.47) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL4047833 | 0.83 | CA1 (0.47) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL14167474 | 0.83 | CA1 (0.47) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL19021911 | 0.82 | CA1 (0.58) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL902049 | 0.82 | CA1 (0.58) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL25231724 | 0.80 | CA1 (0.51) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL22337395 | 0.80 | CA1 (0.51) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL25278428 | 0.80 | CA1 (0.51) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL13744904 | 0.80 | CA1 (0.51) | CA2CA1CA7CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CA2 2520/4885CA1 3042/4885CA7 2286/4885 |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | CA2 2427/4885CA1 2688/4885CA7 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.